ReviewCurrent infectious disease reports2019
Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure.
Review in Current infectious disease reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07408271 (The Impact of Rabeprazole-based Triple Therapy Plus Bismuth for First-line Helicobacter Pylori Eradication on the Vaginal Microecology Change), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of Rabeprazole-based Triple Therapy Plus Bismuth for First-line Helicobacter Pylori Eradication on the Vaginal Microecology Change: a Prospective, Randomized Controlled Trial
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Guideline
- State-of-the-Art Review: Managing Vulvovaginal Candidiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Microbiota Transplantation as a Future Novel Therapeutic Strategy Approach.Diseases (Basel, Switzerland) · 2026Review
- pHyph, a novel antibiotic-free treatment for bacterial vaginosis, promotes Lactobacillus growth and reduces the abundance of pathogens in the vagina.AJOG global reports · 2025Article
- Genital cutaneous candidiasis versus chronic recurrent vulvovaginal candidiasis: distinct diseases, different populations.Clinical microbiology reviews · 2025Review
- A Fungistatic Strategy Using a Shear-Thinning pH-Responsive CMCS-OHA-Lp/Lr Hydrogel for Vulvovaginal Candidiasis.Pharmaceutics · 2025Article
- The Vaginal Microbiome and Reproductive Health in Adolescents and Adults.Journal of pediatric and adolescent gynecology · 2025Review
- Vaginal Candida albicans infections: host-pathogen-microbiome interactions.FEMS microbiology reviews · 2025Review
- Vulvovaginal candidiasis: knowledge, practices and occurrence among pregnant women receiving antenatal care in a teaching hospital, Ghana.Frontiers in global women's health · 2025Article
- Fundamentals of microbiome-based therapies for reproductive tract inflammatory diseases in domestic animals.Animal reproduction · 2025Review
- Antifungal susceptibility and biofilm production of Candida species- causative agents of female genital tract infections.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.Cell host & microbe · 2024Review
- Article
- The Increasing Trend of Triazole-Resistant Candida from Vulvovaginal Candidiasis.Infection and drug resistance · 2024Article
- Patient characteristics and factors contributing to recurrence of bacterial vaginosis presented in primary care.Family practice · 2023Article
- Antibiotic-induced collateral damage to the microbiota and associated infections.Nature reviews. Microbiology · 2023Review
- Antibiotic-free vaginal microbiota transplant with donor engraftment, dysbiosis resolution and live birth after recurrent pregnancy loss: a proof of concept case study.EClinicalMedicine · 2023Article
- Optimization of a Mucoadhesive Vaginal Gel Containing Clotrimazole Using a D-Optimal Experimental Design and Multivariate Analysis.Polymers · 2023Article
- The right bug in the right place: opportunities for bacterial vaginosis treatment.NPJ biofilms and microbiomes · 2022Review
- Augmented Enterocyte Damage DuringFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewGoal was to review epidemiology, pathophysiology, and prevention of post-antibiotic Candida vulvovaginitis (VVC). RECENT
findingsAntibacterial therapy, whether systemic or locally applied to the vagina, represents the single most frequent and predictable cause or triggering mechanism of symptomatic vulvovaginal candidiasis (VVC). Such initiating mechanisms may precipitate sporadic or recurrent episodes of VVC. In spite of this widely recognized association, the exact mechanism whereby antibiotics of all classes cause acute exacerbation of symptomatic vaginal disease remains largely unstudied and therefore largely unknown. Pathophysiology is hypothesized to be reduction or alteration of vaginal microbiome restraints of yeast colonization, proliferation, and expression of virulence characteristics. The predictable link between antibiotic use and post-antibiotic VVC affords practitioners an opportunity for timely intervention using selective, convenient antimycotics usually drugs but possibly probiotic measures. Indications and limitation of these steps are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.